Researchers at the University of British Columbia have identified a rare inherited mutation in the CDK12 gene that causes aggressive prostate cancer in affected men. The discovery appears in Cancer Discovery.

The team examined genetic data from more than 4,500 people with aggressive prostate cancer and found five unrelated men carrying inherited CDK12 mutations. All five developed metastatic prostate cancer between ages 44 and 62. Researchers confirmed the mutation's role by identifying a distinctive pattern of genetic damage in the patients' tumors that matched loss of CDK12 function.

"What's striking is that every patient we identified with this inherited mutation had already developed metastatic disease by the time they were diagnosed," said Dr. Alexander Wyatt, senior author and associate professor of urologic sciences at UBC.

The inherited mutations appear in approximately one in 1,000 people with aggressive prostate cancer. Despite the low frequency, researchers estimate hundreds of families worldwide carry the mutation.

Notably, existing genetic testing technology can already detect CDK12 mutations. Dr. Wyatt recommended including CDK12 in standard genetic testing panels used to assess hereditary prostate cancer risk. This could allow doctors to identify at-risk family members before cancer develops and enable enhanced screening.

The study also found clues suggesting inherited CDK12 mutations might increase ovarian cancer risk. Several men with the mutation had relatives with ovarian cancer, and researchers identified one person with ovarian cancer who carried an inherited CDK12 mutation and showed the same genetic signature seen in the prostate cancer cases. Additional research is needed to establish the link.